BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Study of MDX-1411 Given Every 14 Days With Pre-medications to Subjects With Clear Cell Kidney Cancer.

Phase 1

Completed

Conditions: Kidney Cancer

Interventions: Biological: MDX 1411

First Posted Date: 2008-04-11

Last Posted Date: 2013-05-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 27

Registration Number: NCT00656734

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
🇺🇸
Beth Israel Deaconness Medical Center, Boston, Massachusetts, United States
🇺🇸
Nevada Cancer Institute, Las Vegas, Nevada, United States

and more 4 locations

The Effect of Omeprazole on the Pharmacokinetics of Dasatinib in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Dasatinib + Omeprazole

First Posted Date: 2008-04-10

Last Posted Date: 2009-12-15

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 14

Registration Number: NCT00655746

Locations: 🇺🇸
Bristol-Myers Squibb Clinical Pharmacology Unit, Hamilton, New Jersey, United States

Study to Evaluate KOS-1584 in Patients With Advanced or Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: KOS-1584

First Posted Date: 2008-04-02

Last Posted Date: 2016-05-17

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1

Registration Number: NCT00651508

Locations: 🇺🇸
Consultants In Blood Disorders & Cancer, Louisville, Kentucky, United States

Drug Interaction Study

Phase 1

Completed

Conditions: Antivirals/HIV

Interventions: Drug: Rifabutin + Atazanavir + Ritonavir
Drug: Rifabutin

First Posted Date: 2008-03-31

Last Posted Date: 2013-01-31

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 85

Registration Number: NCT00646776

Locations: 🇺🇸
Bristol-Myers Squibb Clinical Pharmacology Unit, Hamilton, New Jersey, United States

Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism

Phase 3

Completed

Conditions: Venous Thrombosis

Interventions: Drug: Enoxaparin
Drug: Placebo for enoxaparin
Drug: Placebo for warfarin
Drug: warfarin
Drug: Placebo for apixaban
Drug: apixaban

First Posted Date: 2008-03-26

Last Posted Date: 2014-04-21

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 5614

Registration Number: NCT00643201

Locations: 🇺🇸
Pasadena Center For Medical Research, St. Petersburg, Florida, United States
🇺🇸
Great Falls Clinic, Llp, Great Falls, Montana, United States
🇺🇸
Infectious Disease Of Indiana Psc, Carmel, Indiana, United States

and more 71 locations

A Phase I Study of BMS-641988 in Japanese Patients With Castration Resistant Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: BMS-641988 (AR#2)

First Posted Date: 2008-03-26

Last Posted Date: 2011-01-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 7

Registration Number: NCT00644488

Locations: 🇯🇵
Local Institution, Koto-Ku, Tokyo, Japan

Study of the Safety of MDX-1342 in Combination With Methotrexate in Patients With Rheumatoid Arthritis

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Biological: MDX-1342

First Posted Date: 2008-03-20

Last Posted Date: 2013-05-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 26

Registration Number: NCT00639834

Locations: 🇺🇸
Impact Clinical Trials, Los Angeles, California, United States
🇺🇸
Good Samaritan Hospital and Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸
Coastal Medical Research, Inc, Port Orange, Florida, United States

and more 21 locations

Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma

Phase 3

Completed

Conditions: High Risk Stage III Melanoma

Interventions: Drug: Placebo
Drug: ipilimumab

First Posted Date: 2008-03-14

Last Posted Date: 2019-12-17

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1211

Registration Number: NCT00636168

Locations: 🇺🇸
Sharp Memorial Hospital, San Diego, California, United States
🇺🇸
Vanderbilt-Ingram Cancer Ctr, Nashville, Tennessee, United States
🇺🇸
The Angeles Clinic & Research Institute, Los Angeles, California, United States

and more 18 locations

Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Hodgkin's Lymphomas

Interventions: Biological: MDX-1401

First Posted Date: 2008-03-13

Last Posted Date: 2012-12-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 22

Registration Number: NCT00634452

Locations: 🇺🇸
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸
West Virginia University, Morgantown, West Virginia, United States
🇺🇸
ClinWorks Cancer Research Center, Charlotte, North Carolina, United States

and more 3 locations

Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types

Phase 2

Completed

Conditions: Advanced Non-small Cell Lung Cancer
Pancreatic Cancer Including Ampulla of Vater
Transitional Cell Carcinoma
Gastric/Esophageal Adenocarcinoma
Soft Tissue Sarcoma

Interventions: Drug: Placebo
Drug: brivanib

First Posted Date: 2008-03-12

Last Posted Date: 2015-10-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 597

Registration Number: NCT00633789

Locations: 🇬🇧
Local Institution, Surrey, United Kingdom
🇺🇸
Memorial Sloan Kettering Cancer Ctr, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy